Patient P-01602
Synthetic patientNBL-101 · Day 112 · 45–54 · F · baseline S07Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Improving
GI state
Favorable
Inflammatory state
Improving
Nutritional resilience
Declining
Discontinuation risk
10%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S07
- Day 23 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 23.
Primary contributors, last 14 days
- Toxicity-9
- Nutritional resilience-6
- Inflammatory activity-4
- Treatment adherence+2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion10.2/100
improving · -4.2 vs previous 14 d
Toxicity
Blood13.9/100
worsening · +2.0 vs previous 14 d
Sleep quality
Wearable52.2/100
stable · +0.6 vs previous 14 d
Energy level
Daily log6.3/10
stable · -0.2 vs previous 14 d
Stress level
Daily log2.7/10
stable · -0.0 vs previous 14 d
Steps
Wearable4,354
improving · +454 vs previous 14 d
Adherence
Companion84.6 %
worsening · -3.4 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 77 from the failing basin, 47 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
- Daily walks resumedperturbation · steering +3.3
Main detractors to watch
- FUT2 non-secretorhidden · steering -10.6
- IL6 high-expression varianthidden · steering -7.3
- Histamine loadperturbation · steering -7.3
- Spicy / capsaicinperturbation · steering -6.3
- Histamine loaddetractor · GI +5.1 next day
- Spicy / capsaicindetractor · GI +3.9 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load+5.1detractor · 95%
- Spicy / capsaicin+3.9detractor · 95%
- Alcohol+1.6no signal · 32%
- Dietary fat load-0.2no signal · 15%
- Simple carbohydrates+0.2no signal · 15%
- Insoluble fibre-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Inflammatory signalling ↓25
- DNAIL6 -174 variant raises baseline inflammatory tone
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 3.5 · butyrate capacity 47/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 63 ms
- Sleep
- 7.1 h
- Steps
- 3,843
- Resting HR
- 57 bpm
Daily log: GI score 10, nutritional resilience 66, adherence 85.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01773 | 43% | S05 | AD-05 | improved | 27 |
| P-01483 | 39% | S14 | AD-05 | no change | 35 |
| P-01377 | 37% | S11 | AD-05 | no change | 42 |
| P-01541 | 34% | S09 | AD-05 | no change | 43 |
| P-01679 | 33% | S12 | AD-05 | no change | 39 |
| P-01848 | 32% | S05 | AD-05 | no change | 23 |
| P-01804 | 25% | S19 | AD-05 | improved | 61 |
| P-01313 | 42% | S01 | BR-03 | improved | 32 |
| P-01450 | 38% | S09 | BR-03 | no change | 36 |
| P-01350 | 33% | S19 | BR-03 | no change | 34 |
| P-01468 | 32% | S06 | BR-03 | no change | 41 |
| P-01689 | 29% | S13 | BR-03 | no change | 50 |